Jim Cramer on FDA resignations connected to the approval of Biogen’s Alzheimer’s drug

Third FDA advisor resigns after Biogen's Alzheimer's drug approvalПодробнее

Three FDA members resign over Biogen's Alzheimer drug approval: RPTПодробнее

Biogen shares drop as big clinics say they won't administer controversial Alzheimer's drugПодробнее

FDA approves controversial Biogen Alzheimer's drug | DW NewsПодробнее

Breaking down the costs of Biogen's billion-dollar Alzheimer's drugПодробнее

Biogen CEO on FDA approval for its Alzheimer's drugПодробнее

FDA's historic approval of Biogen's Alzheimer's drugПодробнее

Analyst on what Biogen's Alzheimer's drug means for the companyПодробнее

Cramer: Biogen's Alzheimer's treatment would be 'the biggest drug ever'Подробнее

Evidence to approve Biogen's Alzheimer's drug was not 'sufficient': Penn's Dr. Jason KarlawiПодробнее

FDA approves Biogen's Alzheimer's drugПодробнее

Eli Lilly CEO discusses FDA's approval of Biogen's new Alzheimer's drugПодробнее

Biogen shares spike after FDA approves Alzheimer's drugПодробнее

Jim Cramer: There will be push back on Biogen's Alzheimer's drug priceПодробнее

Cantor Fitzgerald's Young on FDA approval for Biogen's Alzheimer drugПодробнее

FDA approves Biogen Alzheimer's treatmentПодробнее

Alzheimer's drug decision day: FDA to decide on Biogen and Eisai treatmentsПодробнее

FDA panel finds Biogen's Alzheimer's drug fails to show effectivenessПодробнее

Jim Cramer on how Lilly's Alzheimer's drug compares to Biogen'sПодробнее